CCM
NUVB icon

CAAS Capital Management’s Nuvation Bio NUVB Stock Holding History

CAAS Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-385,257
Closed -$863K – 918
2022
Q3 		$863K Buy
+385,257
New +$1.1M 0.04% 396

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

CAAS Capital Management's NUVB Position: Q4 2022 in Review

CAAS Capital Management sold out of Nuvation Bio (NUVB) in Q4 2022, closing a stake of 385,257 shares — an estimated $863K sold.

CAAS Capital Management first reported a position in NUVB in Q3 2022 and held it in 1 quarter. The position peaked at $863K in Q3 2022. 126 funds tracked by Wall St. Rank hold NUVB as of Q4 2022.

  • CAAS Capital Management reported no remaining Nuvation Bio position as of Q4 2022 after selling out during the quarter.
  • CAAS Capital Management sold 385,257 Nuvation Bio shares in Q4 2022, an estimated $863K.
  • CAAS Capital Management first reported a position in Nuvation Bio in Q3 2022 and held it in 1 quarter.
  • CAAS Capital Management's Nuvation Bio position peaked at $863K in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.